
Radiation Oncologist, Ballarat Austin Radiation Oncology Centre • Views my own #radonc 🇦🇺
Victoria, Australia
Joined July 2014
- Tweets1.4K
- Following374
- Followers2K
- Likes732
V interesting article, suspect a lot of practice variation here #radonc @TylerSbrt @alison_tree @jryckman3
New in #practicalRO: Peri-rectal Nodal Clinical Target Volume (CTV) Delineation in Patients with Prostate Cancer. #radonc tinyurl.com/probjdavis
1
671
Might this now be possible with the POSEIDON dataset @AmarUKishan?
Calculator showing 10yr MFS with RT (+/- HT) based on pre RT PSA & path features would be v useful, pending widely avail biomarker #radonc #pcsm
1
556
Would be really helpful to be able to generate individualised estimates of MFS/PCSS/OS for salvage RT alone (beyond the subgroup data from Supp Table 4). Any plans for a nomogram/calculator, or suggestions re how to go about this? #radonc #pcsm
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
sciencedirect.com/science/ar…
This systematic review and meta-analysis by the DADSPORT Collaboration evaluated the impact of hormone therapy (HT) added to postoperative radiotherapy (RT) in nonmetastatic #ProstateCancer across five randomized controlled trials involving 4,411 participants. While HT did not significantly improve overall survival (OS) in the general population, it did show meaningful benefits in metastasis-free survival (MFS) and prostate cancer–specific survival (PCSS), each with a 4% absolute improvement at 8 years.
Notably, OS benefits may be limited to patients with higher pre-RT PSA levels or CAPRA-S scores.
These findings support the use of adjuvant HT to improve cancer outcomes, particularly in higher-risk patients.
@DrSpratticus
@AmarUKishan
@drjefstathiou
@PCaParker
@_APollack
@PaulSargos
@felixfengmd
@OncoAlert
@Silke_Gillessen @AOmlin
@nataliagandur @bavilima
Curious to hear from #radonc re whether they contour & limit lumbosacral plexus when boosting involved pelvic nodes in #prostatecancer? (e.g PEACE V used 65Gy/25# which is 74.75Gy EQD2 for a/b=2) 🤔 @alison_tree @PBlanchardMD @piet_ost @dr_alimuhammad @TylerSbrt
OCUM trial n=~1100 but majority not informative re RT omission. Key group n=257, stage II/III <12cm from verge treated with upfront surg (MRF>1mm, no T4 or low T3, vast majority N≤1 & 6-12cm from verge) ➡️ 5yr LR 3.8%. No info re T3 substage/EMVI ascopubs.org/doi/full/10.120… #radonc
Expect substantial overlap with PROSPECT-eligible patients (nejm.org/doi/10.1056/NEJMoa2…) #radonc
4
391
Jonathan Tomaszewski retweeted
Let's have a closer look 🧐at the PROSPECT trial after its presentation at #ASCO23 and publication in @NEJM bit.ly/43L83oI #radonc #crcsm 1/n
Jonathan Tomaszewski retweeted
🚨🚨🚨 PROSPECT Trial has landed!
Congratulations to all investigators, @ALLIANCE_org, for this important trial!
This study is important, will shape, and SHOULD alter practice for OPERATIVELY managed patients with favorable risk LA- rectal cancer.
nejm.org/doi/full/10.1056/NE…
Jonathan Tomaszewski retweeted
New ESTRO ACROP GUIDELINE on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer! Great work!! @a_dalpra @agomeziturriaga @AlbertoBossial sciencedirect.com/science/ar…
Jonathan Tomaszewski retweeted
My arguments presented this morning #EAU23 for #radiotherapy + ADT/ARPA in patients with localized high risk PSMA-N1 BRCA mutated #prostatecancer.
Major thanks to all who provided input!
Two parts:
1. RT/ADT/ARPA is SOC
Hey #prostatecancer tweeps, I need your help to support the use of #radiotherapy at a debate at next EAU meeting...
topic:
49 yo pt with germline BRCA2 mutation
cT3a
PSA 45
ISUP2
N0 on CI but N1 on PSMA
M0
arguments + references much appreciated...
Full time consultant position available - join our team in Ballarat! 🇦🇺👇
https://teapawt.org/t.co/ud5zl18yBp
280
Would interpret with great caution. Small numbers, retrospective & conflicts with randomised data incl RAPIDO showing equivalent QoL/LARS/late GI tox (https://teapawt.org/t.co/SihQjTUheJ) #radonc #rectalcancer
Read our work on bowel functional outcomes after short or long-course radiation for rectal cancers in @DCRjournal from @TataMemorial
Greater incidence of any low anterior resection syndrome after SCRT, similar incontinence
@DCREdInChief @TechColoproctol @ColorectalDis
Fantastic overview of recent & historical loc adv #rectalcancer trials & framework for TNT decision-making #radonc #gicsm @tarik_sammour
Hey Friends! Let’s discuss management of locally advanced rectal cancer! #RadOnc #GIOnc
Check out the results of this poll!
teapawt.org/KrishanJethwa/status/1…
Let’s dive in to review!
🧵 🧵
1/
Respected voices in #skincancer #radonc offering their perspective and urging caution re wide field RT/VMAT for “skin field cancerisation” https://teapawt.org/t.co/9yOGBF3Vno
Wonder if #dermtwitter has any thoughts to share on this thread? 👇 @MDJenniferChoi
Think RT likely to be safe in pts with albinism but will tag others for their thoughts @Sushilberiwal @CatharineWest3 @xrtGenomics @carmenbergom @HenningWillers #radonc
1
Think RT likely to be safe in pts with albinism but will tag others for their thoughts @Sushilberiwal @CatharineWest3 @xrtGenomics @carmenbergom @HenningWillers #radonc
hello #radonc and #medtwitter community! may I ask you a question please! Do you have any experience in treating patients having albinism for prostate #pcsm cancer with radiotherapy ? Do you think that there is any major risk of toxicity or second cancers?Thank you for answering!
A recurring discussion - such is the nature of Twitter (https://teapawt.org/t.co/wDC9kaLblV). Inevitably #radonc will come across as defensive, so pleasing to see perspective offered by Urologists in this thread @uroegg @chrisfilson_uro @ChapinMD
This Post is from an account that no longer exists. Learn more
3
"We, therefore, conclude that higher CV risk should be managed optimally in the CV sense but this finding should not be an indication for the preferential use of LHRH an- tagonists in patients with prostate cancer."
#pcsm #prostatecancer @JCO_ASCO
ascopubs.org/doi/full/10.120…
4































